Oncology tops $84B, Mounjaro surges 124%: Your guide to the 2025 pharma landscape.
FY2024 reset the competitive landscape in pharma. While oncology held its top sales standing, the rapid ascent of GLP-1s, market erosion from Humira biosimilars, and the advance of new modalities revised the new biopharma hierarchy. This deep-dive report builds on the Pharma 50 FY2024 ranking of the top 50 pharmaceutical companies by revenue with the following:
- A full data table of the top 50 blockbuster drugs, detailing sales, manufacturer and year-over-year growth rates.
- Strategic analysis of five core therapeutic areas: Oncology, metabolic, immunology, cardiovascular and rare diseases. Each analysis provides dedicated sales and market share data.
- Data visualizations identifying high-momentum drugs and major decliners, showing both percentage growth and absolute dollar change.
- An analysis of catalysts for 2025, including pipeline milestones, patent expiries and regulatory pressures.
Download the report by filling out the form below.
Sponsored By:
"*" indicates required fields
By clicking 'Submit' above and registering for this content, I acknowledge and agree to WTWH Media's Terms and Conditions and to WTWH Media's use of my contact information to communicate with me about offerings by WTWH Media, its brands, affiliates and/or third-party partners, consistent with WTWH Media's Privacy Policy. In addition, I understand that my personal information may be shared with any sponsor(s) of the content, and that they may contact me directly about their products or services. Please refer to the privacy policies of such sponsor(s) for more details on how your information will be used by them.
Filed Under: Gated Downloads, Pharma 50
